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pn 1998, mapping studies identified the pulmonary veins
n the left atrium as the most prevalent spontaneous
nitiation points of atrial fibrillation (AF) (1). These
tudies led to the development of radiofrequency catheter
blation to eliminate local electrical activity emanating
rom the pulmonary veins as a means of blocking the
ropagation of waves of ectopic activity, thereby reducing
he risk of AF (1). A decade later, mapping studies
dentified loci that increase risk of AF on chromosomes
q25 and 16q22 (2–5).
See page 747
AF affects approximately 2.3 million people in the
.S., and is estimated to increase 5-fold by 2050 as the
opulation ages (6). Catheter ablation is a relatively new
rocedure that is increasingly being implemented in
ospitals around the world. This surgical procedure is
urrently directed toward symptomatic patients in whom
harmacologic therapies have failed. A recent compara-
ive effectiveness analysis of radiofrequency catheter ab-
ation for AF suggested that catheter ablation was effec-
ive at restoring and maintaining sinus rhythm in patients
ainly with paroxysmal AF in whom medical therapy
ailed (7). This comparative analysis of 8 trials included
pproximately 2,000 patients with paroxysmal and per-
istent AF, various ablation techniques, diverse medical
reatments, and different clinical outcomes assessed in
onuniform fashion (8 –15). In brief, heterogeneity, in
hese trials, including inconsistent monitoring of AF
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R01HL092577.ecurrence after ablation, has limited progress. In addi-
ion, it should be noted that the majority of individuals
ncluded in the trials were young (mean age approxi-
ately 55 years), were without major structural heart
isease (normal systolic function and minimally enlarged
eft atrium (5 cm), and had only short-term follow-up
1 year or less). Hence, the generalizability of the findings
o the vast majority of individuals with AF and the
ong-term efficacy of radiofrequency ablation is uncertain.
ur understanding of the frequency of AF recurrence and
echanisms that lead to AF recurrence in patients also is
ncomplete (7,16). The Heart Rhythm Society consensus
tatement has called for additional studies to determine
he long-term efficacy outcomes for ablation (16).
Because of the high cost and potential morbidity and
ortality of radiofrequency catheter ablation, it is highly
esirable to identify pre-procedural characteristics that
ill risk stratify for procedural efficacy and lack of
omplications. There have been hundreds of articles
eporting dozens of putative factors associated with AF
ecurrence after ablation. Some of the reported risk
actors associated with AF recurrence include AF type
paroxysmal vs. persistent and permanent) (17,18), clin-
cal characteristics (e.g., weight and hypertension) (18 –
0), biomarkers (C-reactive protein, natriuretic peptide)
19,21), electrical substrate (P-wave dispersion and trig-
ering of the pulmonary vein) (22,23), nutrition (omega-
-polyunsaturated fatty acid supplements) (24), medica-
ions (angiotensin-converting enzymes or angiotensin
eceptor blockers) (25), and cardiac structural changes
left atrial enlargement, structural heart disease) (17–
9,23,26). Although these factors are associated with AF
ecurrence, the ability of these factors to accurately risk
tratify individuals is untested.
In their study in this issue of the Journal, Husser et al.
27) included 195 individuals with primarily paroxysmal
F who underwent AF ablation and were then moni-
ored by 7-day Holter recordings, immediately after the
rocedure and at 3 and 6 months, to detect AF recur-
ences (7-day Holter monitoring is directly in line with
t
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atheter and Surgical Ablation of Atrial Fibrillation
16]). Within 7 days, 37% of the patients had experienced
F. At 3 to 6 months after the procedure, 21% of
atients had experienced AF. The presence of either of
he polymorphisms on chromosome 4q25 was associated
ith increased risk for both early and late AF (between 3
nd 6 months). Prior reports (28) have noted that
ecurrence of AF is common early after catheter ablation
nd occurs in up to 35% of patients during the first 3.5
ays of follow-up. The mechanisms by which recurrence
f AF occurs after catheter ablation are unknown.
Determining whether the presence or frequency of early
F recurrence is linked to adverse outcomes and treatment
ailure would be an important next step. Although early
ecurrence carries an independent risk of treatment failure,
t present there are no consensus strategies for the moni-
oring, prevention, or treatment of early post-ablation AF
16). Husser et al. (27) provide evidence in a small cohort
hat the presence of either of the variant single nucleotide
olymorphisms (SNPs), rs2200733 and rs10033464, on
hromosome 4q25 was an independent predictor of both
arly and late AF after cardiac ablation. The study con-
rmed previous findings that early and late AF recurrence
re related phenomena and that both types of recurrence
ay share common genetic risks. More importantly, how-
ver, this study by Husser et al. (27) may provide further
mpetus to include a genetic arm in the next generation of
arge trials, including the CABANA (Catheter Ablation
ersus antiarrhythmic Drug for Atrial Fibrillation) trial
NCT00578617).
The study by Husser et al. (27) introduces risk variants
n chromosome 4q25 as potential new factors associated
ith AF recurrence after cardiac ablation. The study has
any strengths, including the prospective design, the
onsecutive series, and the systematic assessment for
ecurrent AF with Holter monitoring. However, the
tudy has many of the design features limiting earlier
tudies reporting putative risk factors for AF recurrence.
he study had a modest sample size (n  195), hence the
tudy’s refutation of clinical and echocardiographic fea-
ures that have been widely reported to be associated with
F recurrence after ablation (e.g., advanced age and left
trial enlargement) were underpowered and should be
iewed with skepticism. In addition, the cohort enrolled
n the study by Husser et al. (27) was homogenous in
egard to the high proportion of lone paroxysmal AF, left
entricular ejection fractions (55% to 63%), sex (primarily
ale), and age (approximately 55 years of age), again
aising questions of the applicability of the findings to the
ajority of individuals affected with AF.
Many times in the literature, the first to publish incurs
he “winner’s curse” (29). In other words, the initial
eports may show the most spectacular findings; however,
he yield of multiple studies averaged over time may show
ore modest results. Prior to the age of genome-wide pssociation studies, 13 candidate loci or genes were
escribed by linkage or candidate gene approaches to be
ssociated with AF (see the recent review by Ellinor et al.
30]), none of which have been replicated in subsequent
tudies. In contrast, the risk variants associated with AF
n chromosome 4q25 originally identified in Icelanders
4) with genome-wide association methods have been
eplicated in individuals from Northern Europe and Asia
s well as in the U.S., Germany, and the Netherlands
5,31). However, the study by Husser et al. (27) represent
he first study to show an association of these risk variants
n 4q25 with recurrence of AF after catheter ablation.
As we continue to improve clinical phenotyping to
ssess new risk markers, equal emphasis and rigor will
eed to be placed on genomic factors. For example,
ncestral differences in populations may help us narrow
aplotypes and define causative alleles, thereby gaining
nsight into the biology (3,4). More information on sex
ifferences in AF recurrence and how genetics may or
ay not be involved also is needed. The individuals in the
tudy by Husser et al. (27) were only typed for 2 SNPs on
q25. Recent work by Gudbjartsson et al. (2) and
enjamin et al. (3) provides evidence for a new SNP on
hromosome 16q22 that also is associated with increased
isk for AF. Along this line, it is likely that additional
ariants associated with increased risk for AF are yet to be
efined. Finally, this study is a single-center study that
ocuses on the relationships between 2 genetic variants
nd the risk of AF after ablation therapy with a relatively
mall number of homogenous patients (n  195). Thus,
call for clinical research studies in larger, more diverse
opulations will help to increase the generalizability of
hese findings and our overall understanding of the role of
enetic risk factors in AF recurrence.
A goal for the near future is a robust clinical risk
rediction algorithm that can be used routinely in the
linic to guide use of catheter ablation therapy and
mprove clinical outcome for patients with AF. A pre-
equisite is developing a robust clinical risk prediction
odel for predicting success using easily available clinical
henotypes such as PR interval, blood pressure measure-
ents, and body mass index. Such a clinical model will
erve as a benchmark to evaluate the incremental yield for
isk prediction of more novel and costly markers such as
atriuretic peptides, C-reactive protein, other plasma
iomarkers, and biological variation in deoxyribonucleic
cid, ribonucleic acid, and protein. The updated recom-
endations for assessing the added predictive ability of a
isk marker, such as a genotype, have been reviewed by
encina et al. (32,33), and include 2 new ways to assess
he usefulness of a new marker: improved integrated
ensitivity without sacrificing specificity and event-
pecific reclassification (32). In addition to new statistical
ethods to assess the usefulness of a new marker, a recent
eport by Hlatky et al. (34) provides guidelines on the 6
hases of evaluation of a novel risk marker. These phases
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ental value, clinical utility, clinical outcomes, and cost
ffectiveness (34). A framework to assess new risk mark-
rs for AF has recently been developed (35). If indeed
enetic variants may serve as risk markers of specific
ulmonary vein phenotypes associated with distinct AF,
ne could envision strategies for which genetic informa-
ion could direct modifications in ablation or post-
blation strategies.
Even if putative risk factors do not aide in risk
rediction over and above standard clinical factors, if they
re associated with efficacy, they may provide important
athophysiologic insights and therapeutic targets. If the
enetic variants on chromosome 4q25 reported by Husser
t al. (27) are validated as predictors of AF recurrence,
he report will raise new questions regarding mechanisms
f disease. A nearby gene, PITX2, has received consid-
rable attention as a prime biological mechanism through
hich these SNPs are increasing risk of AF. However,
upportive evidence for this is lacking. An elegant series
f experiments by Mommersteeg et al. (36) using state-
f-the-art models showed that in the absence of Pitx2,
he formation and expansion of the pulmonary myocar-
ium, which gives rise to the pulmonary veins, does not
ccur. Mommersteeg et al. (36) provide further evidence
hat Pitx2 is required for the differentiation of mesen-
hymal cells into pulmonary myocardium. Mice lacking
itx2 fail to initiate cell proliferation around the pulmo-
ary veins (36). Despite this evidence in a mouse model
acking Pitx2, the mechanism of how variants near this
ene on chromosome 4q25 cause AF has not been
esolved. In fact, at this stage, PITX2 remains a prime
uspect, without any hard evidence in humans that these
NPs induce alterations in PITX2 that lead to increased
isk of AF. More work in this area to help define the
natomy of the pulmonary veins and the function of the
ells comprising the pulmonary veins in humans with and
ithout the variants will be critical.
In sum, Husser et al. (27) have introduced risk variants
n chromosome 4q25 associated with AF recurrence after
atheter ablation. This study raises new questions in the
eld regarding the biological mechanisms of AF recur-
ence and the current limitations in the field. Future
tudies examining the utility of novel clinical or genetic
arkers to predict and risk stratify for ablation efficacy
ill need to be conducted in larger, more diverse popu-
ations, must use robust risk prediction metrics, and
hould replicate their findings in independent cohorts.
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